Table 1.
Baseline clinical characteristics.
| Patient characteristics (N = 21) | DCB (N = 9) | NDB (N = 12) |
|---|---|---|
| Age (years), median (range) | 64 (58–79) | 64 (46–71) |
| Gender | ||
| Male | 7 (78%) | 8 (67%) |
| Female | 2 (22%) | 4 (33%) |
| Histology | ||
| Non-squamous | 7 (78%) | 5 (42%) |
| Squamous | 2 (22%) | 7 (58%) |
| Smoking status | ||
| Current/former | 7 (78%) | 9 (75%) |
| Never | 2 (22%) | 3 (25%) |
| Stage | ||
| IIIB | 3 (33%) | 4 (33%) |
| IV | 6 (67%) | 8 (67%) |
| PD-L1 expression | ||
| 0% | 2 (22%) | 4 (33%) |
| 1–50% | 4 (44%) | 5 (42%) |
| ≥50% | 3 (33%) | 3 (25%) |
| Genotypes | ||
| EGFR mutation | 0 | 1 (1%) |
| ALK fusion | 0 | 0 |
| Prior systemic therapy | ||
| 1 | 5 (50%) | 5 (46%) |
| 2 | 2 (20%) | 2 (18%) |
| 3 | 1 (10%) | 2 (18%) |
| ≥4 | 1 (10%) | 2 (18%) |